Proteomic analysis of human epithelial ovarian cancer xenografts in immunodeficient mice exposed to chronic psychological stress

Science China Life Sciences

Volumn 54, Issue 2, 2011, Pages 112-120

  Gao, Jun ^a   Gao, Guo Lan ^b   Zhang, Yan Yu ^a   Wang, Fen ^a  

^a NANCHANG UNIVERSITY   (China)

^b Aviation General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MUS; MUS MUSCULUS;

EID: 79951567973     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-4126-x     Document Type: Article

References (47)

1. Lynch H T, Casey M J, Lynch J, et al. Genetics and ovarian carcinoma. Semin Oncol, 1998, 25: 265-280.
2. Li Z, Zhao X, Yang J, et al. Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain. Sci China Ser C-Life Sci, 2005, 48: 648-657.
3. Kiecolt-Glaser J K, Robles T F, Heffner K L, et al. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Ann Oncol, 2002, 13: 165-169.
4. Antoni M H. Psychoneuroendocrinology and psychoneuroimmunology of cancer: plausible mechanisms worth pursuing. Brain Behav Immun, 2003, 17: 84-91.
5. Boyce E A, Kohn E C. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer, 2005, 15: 266-273.
6. Philip R, Murthy S, Krakover J, et al. Shared Immuno-proteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res, 2007, 6: 2509-2517.
7. Gortzak-Uzan L, Ignatchenko A, Evangelou A I, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res, 2008, 7: 339-351.
8. Zhu Y, Wu R, Sangha N, et al. Classifications of ovarian cancer tis sues by proteomic patterns. Proteomics, 2006, 6: 5846-5856.
9. Wang J, Zhang X, Ge X, et al. Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol, 2008, 111: 111-119.
10. Young T, Mei F, Liu J, et al. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene, 2005, 24: 6174-6184.
11. Jackson D, Craven R A, Hutson R C, et al. Proteomic profiling identifies afamin as a potential biomarkerfor ovarian cancer. Clin Cancer Res, 2007, 13: 7370-7379.
12. Davidson B, Espina V, Steinberg S M, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res, 2006, 12: 791-799.
13. Ye B, Cramer D W, Skates S J, et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res, 2003, 9: 2904-2911.
14. Uys J D, Hattingh S M, Stein D J, et al. Large scale hippocampal cellular distress may explain the behavioral consequences of repetitive traumatic experiences-a proteomic approach. Neurochem Res, 2008, 33: 1724-1734.
15. Teague C R, Dhabhar F S, Barton R H, et al. Metabonomic studies on the physiological effects of acute and chronic psychological stress in Sprague-Dawley rats. J Proteome Res, 2007, 6: 2080-2093.
16. Carboni L, Piubelli C, Pozzato C, et al. Proteomic analysis of rat hippocampus after repeated psychological stress. Neuroscience, 2006, 137: 1237-1246.
17. Masters J R, Thomson J A, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for cell lines. Proc Natl Acad Sci USA, 2001, 98: 8012-8017.
18. Park S J, Kim M J, Kim H B, et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol, 2009, 77: 1328-1336.
19. Stangelberger A, Schally A V, Varga J L, et al. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res, 2005, 11: 49-57.
20. Alfonso J, Frick L R, Silberman D M, et al. Regulation of hippocampal gene expression is conserved in two species subjected to different stressors and antidepressant treatments. Biol Psychiatry, 2006, 59: 244-251.
21. Sheridan J F, Dobbs C, Jung J, et al. Stress-induced neuroendocrine modulation of viral pathogenesis and immunity. Ann NY Acad Sci, 1998, 840: 803-808.
22. Kim S, Park Y W, Schiff B A, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res, 2005, 11: 1713-1721.
23. Winter D, Kugelstadt D, Seidler J, et al. Protein phosphorylation influences proteolytic cleavage and kinase substrate properties exemplified by analysis of in vitro phosphorylated Plasmodium falciparum glideosome-associated protein 45 by nano-ultra performance liquidchromatographytandem mass spectrometry. Anal Biochem, 2009, 393: 41-47.
24. Culp W D, Neal R, Massey R, et al. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res, 2006, 5: 1332-1343.
25. Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res, 2003, 1: 682-689.
26. Kim J H, Bogner P N, Baek S H, et al. Up-regulation of peroxiredoxin1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res, 2008, 14: 2326-2333.
27. Kang D, Lee K M, Park S K, et al. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev, 2007, 16: 1581-1586.
28. Hirose K, Longo D L, Oppenheim J J, et al. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J, 1993, 7: 361-368.
29. Brown D P, Chin-Sinex H, Nie B, et al. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol, 2009, 63: 723-730.
30. Durany N, Joseph J, Jimenez O M, et al. Phosphoglycerate mutase, 2, 3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br J Cancer, 2000, 82: 20-27.
31. Hwang T L, Liang Y, Chien K Y, et al. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics, 2006, 6: 2259-2272.
32. Tang S J, Ho M Y, Cho H C, et al. Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int J Cancer, 2008, 123: 2840-2848.
33. Pogue-Geile K, Geiser J R, Shu M, et al. Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol, 1991, 11: 3842-3849.
34. Marty L, Taviaux S, Fort P. Expression and human chromosomal localization to 17q25 of the growth-regulated gene encoding the mitochondrial ribosomal protein MRPL12. Genomics, 1997, 41: 453-457.
35. Youn B S, Kim D S, Kim J W, et al. NM23 as a prognostic biomarker in ovarian serous carcinoma. Mod Pathol, 2008, 21: 885-892.
36. Schneider J, Pollán M, Jiménez E, et al. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer, 2000, 82: 1662-1670.
37. Castagna A, Antonioli P, Astner H, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics, 2004, 4: 3246-3267.
38. Satoh K, Narumi K, Abe T, et al. Diminution of 37-kDa laminin binding protein expression reduces tumour formation of murine lung cancer cells. Br J Cancer, 1999, 80: 1115-1122.
39. Young L J, Lee E Y, To H A, et al. Human esterase D gene: complete cDNA sequence, genomic structure and application in the genetic diagnosis of human retinoblastoma. Hum Genet, 1988, 79: 137-141.
40. Xia C, Meng Q, Liu L Z, et al. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res, 2007, 67: 10823-10830.
41. Zhou X, Liu Y, You J, et al. Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Lett, 2008, 270: 312-327.
42. Ren K, Jin H, Bian C, et al. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem, 2008, 283: 35598-35605.
43. Myung J K, Afjehi-Sadat L, Felizardo-Cabatic M, et al. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci, 2004, 2: 8-13.
44. Ando T, Ishiguro H, Kimura M, et al. Decreased expression of NDRG1 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Dis Esophagus, 2006, 19: 454-458.
45. Ellen T P, Ke Q, Zhang P, et al. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis, 2008, 29: 2-8.
46. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 2005, 8: 355-368.
47. Ouellet V, Le Page C, Guyot M C, et al. SET complex in serous epithelial ovarian cancer. Int J Cancer, 2006, 119: 2119-2126.